Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience

Background Patent expiries on leading biologics are creating new momentum in the market for biosimilars (copies of off-patent biologics), paving the way for their development. However, little is known about the factors influencing the competition between biosimilars and their reference products (REF).